Tongji Hospital affiliated to Tongji Medical College of Huazhong University Trials

Tongji Hospital affiliated to Tongji Medical College of Huazhong University	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Zhang, Wanguang

NCT06311929: Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma

Recruiting

300

RoW

PD-1 monoclonal antibody and lenvatinib, Non, PD-1 monoclonal antibody

Chen Xiaoping

HCC

12/27

12/28

NCT06311942: Triple vs. Dual Adjuvant Therapy Following Liver Resection for HCC.

Recruiting

300

RoW

HAIC plus PD-1 inhibitors plus lenvatinib, Non, PD-1 inhibitors plus lenvatinib

Chen Xiaoping

HCC

12/27

12/28

CCGLC-005, NCT05236699: A Clinical Study of DEB-TACE Combined With Surufatinib and Camrelizumab in the Treatment of Inoperable or Metastatic ICC

Recruiting

RoW

DEB-TACE combined with Surufatinib and Camrelizumab

Tongji Hospital

Intrahepatic Cholangiocarcinoma

06/24

01/25

CCGLC-010, NCT05839197: A Single-arm Clinical Study of HAIC Combined With Apatinib and Camrelizumab in the Treatment of Unresectable MTM HCC

Recruiting

RoW

HAIC, hepatic arterial infusion chemotherapy of FOLFOX, Camrelizumab plus Apatinib

Wan-Guang Zhang

Macrotrabecular Massive Hepatocellular Carcinoma

04/25

NCT06463444: Precision Treatment of Unresectable HCC Guided by Multi-omics Deep Learning Models

Recruiting

RoW

HAIC + Tislelizumab +lenvatinib

Chen Xiaoping

HCC, Precision Therapy

06/25

06/26

NCT06248554: Adjuvant PD-1 Inhibitor for Patients With Early-stage Hepatocellular Carcinoma Following Microwave Ablation

Recruiting

N/A

200

RoW

PD-1 Inhibitors

Chen Xiaoping

Hepatocellular Carcinoma

10/24

12/24

CHALLENGE-01, NCT06248528: Comparing the Prognosis of Patients With HCC and PVTT Treated With Surgery Versus Locoregional Therapy.

Recruiting

N/A

200

RoW

Liver resection, Locoregional therapy

Chen Xiaoping

Hepatocellular Carcinoma

10/24

12/24

NCT05292443: Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer

Withdrawn

N/A

300

RoW

Observation

Geneplus-Beijing Co. Ltd., Eastern Hepatobiliary Surgery Hospital

Primary Liver Cancer, Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Combined Hepatocellular-cholangiocarcinoma

03/23

CCGLC-001, NCT05713994: Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma

Recruiting

N/A

300

RoW

HAIC, hepatic arterial infusion chemotherapy of FOLFOX, Bevacizumab plus Atezolizumab, Avastin plus Tecentriq, Bevacizumab Biosimilar IBI305 plus sintilimab, Byvasda (B) plus S, Lenvatinib, Lenvima, Sorafenib, Nexavar, Donafenib, Zepsun, Regorafenib, stivarga, apatinib plus camrelizumab, Apa plus C, Anti-PD-1 monoclonal antibody, PD-1 inhibitor

Wan-Guang Zhang, Chinese Cooperative Group of Liver Cancer (CCGLC), Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province, Haplox Biotechnology Co., Ltd., Geneplus-Beijing Co. Ltd., The Second Affiliated Hospital of Fujian Medical University

Hepatocellular Carcinoma Non-resectable

04/24

12/24

CCGLC-006, NCT05520788: Ambispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequencing

Recruiting

N/A

200

RoW

precise medicine

Tongji Hospital

Hepatocellular Carcinoma, Biliary Tract Cancer

12/25



	Diseases Companies Products Productz Mechanisms of Action Sites